Aimmune Therapeutics Inc (AIMT.OQ)
16 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2015||Independent Chairman of the Board|
|57||2016||President, Chief Executive Officer, Director|
|57||2017||Chief Financial Officer|
|51||2016||Chief Operating Officer|
|59||2016||Senior Vice President, General Manager of Europe|
- BRIEF-Aimmune Therapeutics Qtrly Loss Per Share $0.81
- BRIEF-Aimmune Therapeutics Announces Pricing Of Public Offering Of Common Stock
- BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock
- UPDATE 2-Aimmune's peanut allergy drug meets main goal, shares surge
- BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy